[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659342":3},{"organization":4,"outcomesModule":7,"designInfo":37,"detailedDescription":11,"studyPopulation":11,"armGroups":44,"interventions":95,"overallOfficials":11,"centralContacts":138,"locations":144,"responsibleParty":162,"collaborators":11,"id":164,"slug":165,"hasResults":166,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":11,"eligibilityCriteria":169,"healthyVolunteers":166,"sex":170,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":11,"studyType":176,"phases":177,"briefSummary":179,"conditions":180,"keywords":11,"overallStatus":182,"whyStopped":11,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},{"fullName":5,"class":6},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":22,"otherOutcomes":11},[9,13,15,18,20],{"measure":10,"description":11,"timeFrame":12},"Part A1 : pCR rate;",null,"about 24 months",{"measure":14,"description":11,"timeFrame":12},"Part A2 : 2-year DFS rate;",{"measure":16,"description":11,"timeFrame":17},"Part A3 : pCR rate and 18-month EFS rate;","about 18 months",{"measure":19,"description":11,"timeFrame":12},"Part B1 : 2-year DFS rate.",{"measure":21,"description":11,"timeFrame":12},"Part B2 : MPR rate.",[23,26,28,31,33,35],{"measure":24,"description":11,"timeFrame":25},"The incidence and grade of adverse events;","about 48 months",{"measure":27,"description":11,"timeFrame":12},"surgical complications;",{"measure":29,"description":11,"timeFrame":30},"EFS","about 24 months ;",{"measure":32,"description":11,"timeFrame":12},"ORR;",{"measure":34,"description":11,"timeFrame":12},"DFS and DFS rates;",{"measure":36,"description":11,"timeFrame":25},"OS ;",{"allocation":38,"interventionModel":39,"interventionModelDescription":40,"primaryPurpose":41,"observationalModel":11,"timePerspective":11,"maskingInfo":42},"RANDOMIZED","PARALLEL","This is a parallel-arm study in which participants are categorized by biomarker profile and treatment stage. Within each cohort, randomization will be applied to determine treatment assignment.","TREATMENT",{"masking":43,"maskingDescription":11,"whoMasked":11},"NONE",[45,50,55,58,61,65,69,72,76,80,83,87,91],{"label":46,"type":47,"description":11,"interventionNames":48},"group A1-1adebrelimab + SHR-A2009","EXPERIMENTAL",[49],"Drug: adebrelimab + SHR-A2009",{"label":51,"type":52,"description":11,"interventionNames":53},"group A1-2 paclitaxel or pemetrexed combined with carboplatin +adebrelimab","ACTIVE_COMPARATOR",[54],"Drug: paclitaxel or pemetrexed combined with carboplatin +adebrelimab",{"label":56,"type":47,"description":11,"interventionNames":57},"group1 A2-1adebrelimab + SHR-A2009 (longer-interval regimen arm)",[49],{"label":59,"type":47,"description":11,"interventionNames":60},"group2 A2-2adebrelimab + SHR-A2009 (shorter-interval regimen arm)",[49],{"label":62,"type":52,"description":11,"interventionNames":63},"group A2-3 adebrelimab",[64],"Drug: adebrelimab",{"label":66,"type":47,"description":11,"interventionNames":67},"group1 A3-1 adebeliizumab + SHR-A2009 (longer-interval regimen arm)",[68],"Drug: adebeliizumab + SHR-A2009",{"label":70,"type":47,"description":11,"interventionNames":71},"group2 A3-2 adebeliizumab + SHR-A2009 (shorter-interval regimen arm)",[68],{"label":73,"type":52,"description":11,"interventionNames":74},"group A3-3 adebeliizumab + platinum-containing double chemotherapy",[75],"Drug: adebeliizumab + platinum-containing double chemotherapy",{"label":77,"type":47,"description":11,"interventionNames":78},"group B1-1 almonertinib combined with SHR-A2009 (longer-interval regimen arm)",[79],"Drug: almonertinib combined with SHR-A2009",{"label":81,"type":47,"description":11,"interventionNames":82},"group B1-2 almonertinib combined with SHR-A2009 (shorter-interval regimen arm)",[79],{"label":84,"type":52,"description":11,"interventionNames":85},"group B1-3 almonertinib",[86],"Drug: almonertinib",{"label":88,"type":47,"description":11,"interventionNames":89},"group B2-1 SHR-A2009 combined with almonertinib",[90],"Drug: SHR-A2009 combined with almonertinib",{"label":92,"type":52,"description":11,"interventionNames":93},"group B2-2 almonertinib monotherapy",[94],"Drug: almonertinib monotherapy",[96,100,103,106,109,112,116,119,122,126,129,132,135],{"type":97,"name":98,"description":98,"armGroupLabels":99,"otherNames":11},"DRUG","adebrelimab + SHR-A2009",[46],{"type":97,"name":101,"description":101,"armGroupLabels":102,"otherNames":11},"paclitaxel or pemetrexed combined with carboplatin +adebrelimab",[51],{"type":97,"name":98,"description":104,"armGroupLabels":105,"otherNames":11},"adebrelimab + SHR-A2009 (longer-interval regimen arm)",[56],{"type":97,"name":98,"description":107,"armGroupLabels":108,"otherNames":11},"adebrelimab + SHR-A2009 (shorter-interval regimen arm)",[59],{"type":97,"name":110,"description":110,"armGroupLabels":111,"otherNames":11},"adebrelimab",[62],{"type":97,"name":113,"description":114,"armGroupLabels":115,"otherNames":11},"adebeliizumab + SHR-A2009","adebeliizumab + SHR-A2009 (longer-interval regimen arm)",[66],{"type":97,"name":113,"description":117,"armGroupLabels":118,"otherNames":11},"adebeliizumab + SHR-A2009 (shorter-interval regimen arm)",[70],{"type":97,"name":120,"description":120,"armGroupLabels":121,"otherNames":11},"adebeliizumab + platinum-containing double chemotherapy",[73],{"type":97,"name":123,"description":124,"armGroupLabels":125,"otherNames":11},"almonertinib combined with SHR-A2009","almonertinib combined with SHR-A2009 (longer-interval regimen arm)",[77],{"type":97,"name":123,"description":127,"armGroupLabels":128,"otherNames":11},"almonertinib combined with SHR-A2009 (shorter-interval regimen arm)",[81],{"type":97,"name":130,"description":130,"armGroupLabels":131,"otherNames":11},"almonertinib",[84],{"type":97,"name":133,"description":133,"armGroupLabels":134,"otherNames":11},"SHR-A2009 combined with almonertinib",[88],{"type":97,"name":136,"description":136,"armGroupLabels":137,"otherNames":11},"almonertinib monotherapy",[92],[139],{"name":140,"role":141,"phone":142,"phoneExt":11,"email":143},"Yijing Chen","CONTACT","18810456365","yijing.chen.yc510@hengrui.com",[145],{"facility":146,"status":11,"city":147,"state":148,"zip":149,"country":150,"countryCode":151,"cosmosGeoPoint":152,"geoPoint":157,"contacts":158},"Guangdong Provincial People's Hospital","Guangzhou","Guangdong","510080","China","CN",{"type":153,"coordinates":154},"Point",[155,156],113.25,23.11667,{"lat":156,"lon":155},[159],{"name":160,"role":161,"phone":11,"phoneExt":11,"email":11},"Yilong Wu","PRINCIPAL_INVESTIGATOR",{"type":163,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100659342","phase-2-an-open-multicenter-phase-ii-clinical-trial-of-shr-a2009-combined-with-other-anti-tumor-therapies-for-perioperative-treatment-of-resectable-non-small-cell-lung-cancer-100659342",false,"NCT07863167","An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.","Inclusion Criteria:\n\n1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;\n2. At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.\n3. The ECOG score was 0 or 1.\n4. Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).\n5. Adequate bone marrow and organ function.\n\nExclusion Criteria:\n\n1. Participants who received systemic immunostimulatory therapy within 4 weeks prior to the first dose.\n2. Participants who received systemic immunosuppressive therapy within 2 weeks before the first dose.\n3. Participants with active, known or suspected autoimmune diseases.\n4. Other malignant tumors within 5 years before screening.\n5. Participants with a history of interstitial pneumonia or cannot exclude interstitial pneumonia; or there are other moderate to severe lung diseases that may affect respiratory function. Or received previous pneumonectomy surgery.\n6. Participants with severe cardiovascular and cerebrovascular diseases.\n7. There were clinically significant bleeding symptoms or obvious bleeding tendency within 1 month before the first administration.\n8. Arterial and venous thrombosis events occurred within 3 months before the first administration.\n9. HIV test positive.\n10. Participants with active hepatitis B or C.\n\n1.Evidence of active tuberculosis infection within 1 year before the first administration.\n\n12.Severe infection occurred within 4 weeks before the first administration. 13.History of severe allergic reactions to other monoclonal antibody \u002F fusion protein drugs.\n\n14\\. Allergy to any component of the treatment regimen. 15.Participants were known to have a history of psychotropic drug abuse, alcohol abuse or drug abuse.","ALL","18 Years","70 Years",{"count":174,"type":175},660,"ESTIMATED","INTERVENTIONAL",[178],"PHASE2","The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.",[181],"Non-small Cell Lung Cancer","NOT_YET_RECRUITING","2026-09-30",{"date":185,"type":186},"2026-10-07","ACTUAL",{"date":188,"type":175},"2026-10-30",{"date":190,"type":175},"2030-12-30",{"name":5,"class":6},1]